J Korean Med Sci.  2007 Feb;22(1):110-113. 10.3346/jkms.2007.22.1.110.

Interleukin-1 Beta -511 Polymorphism and Risk of Cervical Cancer

• Kang S
• Kim JW
• Park NH
• Song YS
• Park SY
• Kang SB
• Lee HP

• KMID: 1713245
• DOI: http://doi.org/10.3346/jkms.2007.22.1.110

Abstract

Cervical cancer is almost invariably associated with infection by human papillomavirus. It is believed that the host genetic factors such as inflammation-induced cytokines may play a role in cervical carcinogenesis. The IL1B gene, encoding IL-1beta cytokine, contains several single nucleotide polymorphisms. One of them which is in the positions -511 (C-T) related with promoter region has been associated with increased IL-1beta production and with increased risk of developing a number of inflammatory diseases and gastric carcinoma. We assessed the association between the IL1B -511 polymorphism and cervical cancer risk in a hospital-based case-control study among 546 Korean women (182 cases; 364 age-matched controls). The allele frequencies of the case subjects (C, 0.42; T, 0.58) were not significantly different from those of control subjects (C, 0.43; T, 0.57). Control subjects were in Hardy-Weinberg equilibrium. The carriers with -511 C/T or T/T genotypes were at higher risk of cervical cancer with odds ratio of 2.42 (95% CI 1.31-4.46, p<0.005). However, there was no difference of cervical cancer risk between C/T heterologous genotypes and T/T homologous genotypes. In conclusion, in Korean population, IL1B -511 C/C genotypes were significantly associated with a decreased risk of cervical cancer.

Keyword

Uterine Cervical Neoplasms; Polymorphism, Genetic; Interleukin-1beta; Disease Susceptibility; Case-Control Studies

MeSH Terms

Uterine Cervical Neoplasms/etiology/*genetics
*Polymorphism, Genetic
Interleukin-1beta/*genetics
Humans
Genotype
Genetic Predisposition to Disease
Female
Case-Control Studies

Reference

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002. 97:72–81.

2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002. 2:342–350.

3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002. 420:860–867.

4. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodriguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001. 10:1021–1027.

5. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsague X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002. 94:1604–1613.

6. Schwebke JR, Zajackowski ME. Effect of concurrent lower genital tract infections on cervical cancer screening. Genitourin Med. 1997. 73:383–386.

7. Bird S, Zou J, Wang T, Munday B, Cunningham C, Secombes CJ. Evolution of interleukin-1beta. Cytokine Growth Factor Rev. 2002. 13:483–502.

8. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000. 404:398–402.

9. Lee KA, Ki CS, Kim HJ, Sohn KM, Kim JW, Kang WK, Rhee JC, Song SY, Sohn TS. Novel interleukin 1 beta polymorphism increased the risk of gastric cancer in a Korean population. J Gastroenterol. 2004. 39:429–433.

10. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simoes M. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002. 94:1680–1687.

11. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004. 109:353–356.

12. Majeed GS, Glew S, Bidwell J. An association between LSIL and the high secretor phenotype of IL-1beta. Gynecol Oncol. 1999. 73:359–361.

13. Tjiong MY, van der Vange N, ter Schegget JS, Burger MP, ten Kate FW, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine. 2001. 14:357–360.

14. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC, Seymour AB. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004. 50:1976–1983.

15. Behbakht K, Friedman J, Heimler I, Aroutcheva A, Simoes J, Faro S. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. Infect Dis Obstet Gynecol. 2002. 10:181–186.

16. Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002. 184:57–63.

17. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, Tswana SA. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001. 94:792–794.

18. Mustea A, Sehouli J, Konsgen D, Stengel D, Sofroni D, Lichtenegger W. Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res. 2003. 23:1099–1102.

19. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003. 13:148–153.

20. Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004. 92:675–679.

21. Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005. 191:969–976.

22. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000. 60:3333–3337.

23. Hybertson BM, Lee YM, Cho HG, Cho OJ, Repine JE. Alveolar type II cell abnormalities and peroxide formation in lungs of rats given IL-1 intratracheally. Inflammation. 2000. 24:289–303.

24. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000. 60:184–190.

25. Simonart T, Van Vooren JP. Interleukin-1 beta increases the BCL-2/BAX ratio in Kaposi's sarcoma cells. Cytokine. 2002. 19:259–266.

26. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003. 37:65–71.